COVID-19 vaccination during pregnancy and neonatal health
Using data from the Dutch Pregnancy Drug Register, Netherlands Pharmacovigilance Centre Lareb found no association between COVID-19 vaccination during pregnancy and the neonatal health outcomes small for gestational age (SGA), large for gestational age (LGA), and neonatal health problems.
During the COVID-19 pandemic, pregnant women in the Netherlands were advised to vaccinate against COVID-19. Lareb studied the association between COVID-19 vaccination during pregnancy, and the health of the child after delivery. We did this using the data of the Dutch Pregnancy Drug Register.
Dutch Pregnancy Drug Register
The Dutch Pregnancy Drug Register is an ongoing cohort study that monitors the safety of drug exposure during pregnancy and breastfeeding. Pregnant women self-reported COVID-19 vaccination and neonatal health outcomes. For the current analyses, we looked at the neonatal health outcomes: SGA at birth (a birthweight below the 10th percentile according to the Dutch reference norms); LGA at birth (a birthweight above the 90th percentile according to the Dutch reference norms); and neonatal health problems (problems with breathing; problems with glucose levels; low muscle tone; high muscle tension; infant jaundice requiring phototherapy; and/or (possible) infection occurring shortly after birth).
COVID-19 vaccination during pregnancy and neonatal health
In total, 3655 participants were included in analyses of whom 92.1% reported to be vaccinated against COVID-19 during pregnancy. COVID-19 vaccination during pregnancy was not statistically significantly associated with SGA (aPR: 0.90; 95% CI: 0.59–1.36), LGA (aPR: 1.07; 95% CI: 0.70–1.63), or neonatal health problems (aPR: 0.84; 95% CI: 0.63–1.11). This study indicates that COVID-19 vaccination during pregnancy is not associated with self-reported adverse neonatal health outcomes.
Read full article here: https://onlinelibrary.wiley.com/doi/10.1002/ped4.12456